News & Events

May 12, 2010

Smith Medical Partners Obtains Agreement to Distribute Leading Oncology Drugs from Endo Pharmaceuticals

National reach and next day delivery is a benefit in the distribution of specialty pharmaceuticals

WOOD DALE, Ill. – Smith Medical Partners is pleased to announce an agreement with Endo Pharmaceuticals to distribute VANTAS^®(histrelin implant), VALSTAR^®(valrubicin) and SUPPRELIN^® LA (histrelin acetate) subcutaneous implant. The addition of these products to Smith Medical Partners’ inventory provides healthcare facilities across the country direct access to these treatments. Smith Medical Partners leverages the benefit of next day delivery in all 50 states, allowing practitioners to receive the product swiftly and reliably.

“Our distribution capabilities provide a secure and efficient channel for the pharmaceuticals to reach the end patient while minimizing overhead expenses for all parties,” said Smith Medical Partners’ Vice President David DuRoss. “We’re proud to be such an integral part of the supply chain.”

A trusted resource for the healthcare community, Smith Medical Partners is equipped to supply a full range of specialty practices. Associates are educated to be able to offer valuable insight on product selection, patient assistant programs and reimbursement. This knowledge and broad focus makes Smith Medical Partners an asset to physicians, clinics, surgery centers, alternate care providers and other healthcare professionals.

About Smith Medical Partners
Smith Medical Partners, a subsidiary of H. D. Smith, is a national distributor of specialty, brand and generic pharmaceuticals; vaccines; injectables; and med/surg materials. Offering a full line of specialty products and business solutions, Smith Medical Partners is serving the front lines of healthcare with reliable distribution and industry experience. Additional information about Smith Medical Partners can be found at smpspecialty.com.

# # #

Contact:
Jorge Valdez
Smith Medical Partners
800.292.9653 x 3212